REG - Novacyt S.A. - Liquidity Agreement and Total Voting Rights

Novacyt SAAnnouncement

01/02/2024 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240201:nRSA7352Ba&default-theme=true

RNS Number : 7352B  Novacyt S.A.  01 February 2024

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Liquidity Agreement Monthly Update and Total Voting Rights

 

Paris, France, Eastleigh and Manchester, UK - 1 February 2024 -
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces its monthly update in relation to ordinary
shares traded under its ongoing liquidity agreement with Invest Securities SA
(the "Liquidity Agreement"). The Liquidity Agreement is governed by French law
and is further summarised below.

 

During the period from 1 January to 31 January 2024, Invest Securities
purchased 43,622 ordinary shares at a maximum price of €0.72 and a minimum
price of €0.55 and sold 27,970 ordinary shares at a maximum price of €0.72
and a minimum price of €0.56 under the Liquidity Agreement. The total number
of ordinary shares in the Company, which are held in treasury as at close of
business on 31 January 2024, is 72,492.

 

Total Voting Rights

 

The total number of ordinary shares in the Company is 70,626,248. This figure
may be used by shareholders as the denominator for calculations by which they
will determine if they are required to notify their interest in, or a change
to their interest in, the Company pursuant to Article L. 223-7 of the French
Commercial Code and the Company's Articles. The Company is not subject to the
disclosure guidance and transparency rules made by the Financial Conduct
Authority under Part VI of FSMA.

 

Contacts

 

 Novacyt SA                                                +44 (0) 23 8074 8830
 James McCarthy, Acting Chief Executive Officer

 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                           +44 (0)20 3470 0470

 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Deutsche Numis (Joint Broker)                                                           +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Michael Palser

 Allegra Finance (French Listing Sponsor)                                                +33 (1) 42 22 10 10
 Rémi Durgetto / Yannick Petit                                                            r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
                                                                                         y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 Walbrook PR (Financial PR & IR)                           +44 (0)20 7933 8780

 Stephanie Cuthbert / Anna Dunphy / Phillip Marriage       novacyt@walbrookpr.com (mailto:novacyt@walbrookpr.com)

 

 

About Novacyt Group (www.novacyt.com (http://www.novacyt.com) )

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical           Broad portfolio of human clinical in vitro diagnostic products, workflows and
                    services focused on three therapeutic areas:

                    ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                    tests

                    ·    Precision Medicine: DPYD genotyping assay

                    ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                    panel

 Instrumentation    Portfolio of next generation size selection DNA sample preparation platforms
                    and rapid PCR machines, including:

                    ·    Ranger® Technology: automated DNA sample preparation and target
                    enrichment technology

                    MyGo: real-time quantitative PCR (qPCR) instruments

 Research Use Only  Range of services for the research industry:

                    ·    Design, manufacture, and supply of high-performance qPCR assays and
                    workflows for use in human health, agriculture, veterinary and environmental,
                    to support global health organisations and the research industry

                    ·    Pharmaceutical research services: whole genome sequencing (WGS) /
                    whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy in France with offices in the UK (in
Stokesley, Eastleigh and Manchester), Taipei (divestment pending), Singapore,
the US and Canada and has a commercial presence in over 65 countries. The
Company is listed on the London Stock Exchange's AIM market ("NCYT") and on
the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

Further information on the Liquidity Agreement

 

On 12 September 2016, the Company and Invest Securities entered into the
Liquidity Agreement pursuant to which Invest Securities provides liquidity
services in relation to the ordinary shares to the Company. Invest Securities
may purchase ordinary shares on behalf of the Company under the agreement,
subject to approval from Shareholders as to the price at which ordinary shares
can be brought back and the aggregate amount that the Company may provide to
Invest Securities to purchase such ordinary shares.

 

Shareholder approval was granted at the Shareholders' meeting held on 20 July
2022 for the purchase of ordinary shares by Invest Securities under the
agreement at a maximum purchase price per ordinary shares of €12.00 for an
aggregate maximum purchase price of €200,000 and for 18 months from the date
of the approval. Under the agreement, Invest Securities must act completely
independently of the Company and the Company must not communicate with the
employees of Invest Securities who are responsible for performing the
agreement. Invest Securities is paid €10,000 per annum for its services
under the liquidity agreement. The agreement has an initial term of two years,
with a rolling extension of one year thereafter. The agreement can be
terminated by either party at the end of each such period subject to two
months' prior notice. The Liquidity Agreement is governed by French law.
Ordinary shares purchased by Invest Securities are either cancelled or held as
treasury shares (which are non-voting and do not rank for dividends).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRFFLFBZLLEBBX